Understand the source comparison
How to Use FOXO4-DRI for Anti-Aging Protocol: Research Comparison
Single high dose (15 mg/kg) 40–50% reduction in SA-β-gal+ cells after 72h One-time administration, assessed at 7 days Broad but uneven. Highest in adipose, lowest in cardiac Effective for short-term clearance but no sustained benefit without repeat dosing Puls
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Single high dose (15 mg/kg)
- 40–50% reduction in SA-β-gal+ cells after 72h
- One-time administration, assessed at 7 days
- Broad but uneven. Highest in adipose, lowest in cardiac
- Effective for short-term clearance but no sustained benefit without repeat dosing
- Pulsed protocol (5–7 mg/kg × 3 days)
- 55–65% reduction in p16^INK4a^ expression at 14 days
- 3 consecutive days, 7–14 day rest, repeat 2–4×
- More uniform across tissues, including vascular endothelium
- Industry standard. Balances efficacy with safety and allows apoptotic clearance between pulses
- Continuous low-dose (2–3 mg/kg daily)
- 20–30% reduction, plateaus after 10 days
- Daily administration for 21 days
- Minimal. Insufficient local concentration for FOXO4-p53 disruption
- Not recommended. Promotes adaptive resistance and offers no advantage over pulsed dosing
- The pulsed 5–7 mg/kg protocol consistently outperforms both single high-dose and continuous low-dose approaches in published senolytic literature. The three-day cycle ensures sufficient peptide exposure to block FOXO4-p53 binding, while the off period allows caspase-mediated apoptosis to complete before the next pulse.